Loading organizations...
Loading organizations...

Casdin Capital: Fundamental research investment firm investing in early-stage to late-stage private and public life sciences and healthcare companies.
Key people at Casdin Capital.
Casdin Capital is a fundamental research investment firm that focuses on early-stage to late-stage private and public companies operating within the life sciences and healthcare sectors. The organization analyzes disruptive technologies and emerging business models to provide capital and strategic expertise to industry leaders across both public and private capital markets. Its investment portfolio features prominent healthcare and biotechnology organizations, including GeneDx, Exact Sciences, Thrive Earlier Detection, Invitae Corporation, and Relay Therapeutics. The firm actively participates in corporate governance and institutional partnerships, maintaining board affiliations with various academic and medical research centers across the United States. Additionally, the firm's leadership joined the board of directors at GeneDx in July 2021 while holding observer roles across various other life sciences enterprises to support their long-term commercial growth. Casdin Capital was founded in 2011 by Eli Casdin.
Casdin Capital is a New York-based fundamental research investment firm founded in 2012 by Eli Casdin, focused on life sciences and healthcare. The firm invests across early-stage to late-stage private and public companies, emphasizing transformative technologies in molecular medicine, biotechnology, genomics, synthetic biology, diagnostics, and precision therapies. Casdin Capital’s mission is to identify and support high-growth companies that leverage scientific innovation to revolutionize healthcare, managing a long-short equity fund and maintaining a portfolio of over 230 investments with a strong track record of successful exits. Their investment philosophy centers on deep fundamental research, long-term conviction, and collaboration with expert management teams to drive impactful advancements in health and biotech sectors[1][2][3][4].
Founded by Eli Casdin, who serves as Chief Investment Officer, the firm has grown to include key partners such as COO Alexandria Fisk and CFO Lawrence Canzoneri. Since its inception, Casdin Capital has evolved by expanding its focus within life sciences to include a broad range of sub-sectors like healthtech, diagnostics, and synthetic biology, while maintaining a rigorous research-driven approach. The firm’s evolution reflects its commitment to staying at the forefront of scientific and technological innovation, leveraging its deep industry expertise and extensive network to identify promising investment opportunities and support portfolio companies through growth and commercialization phases[1][3][6].
Casdin Capital rides the wave of rapid innovation in molecular medicine, biotechnology, and precision healthcare, sectors experiencing accelerated growth due to advances in genomics, synthetic biology, and data analytics. The timing is critical as healthcare increasingly integrates technology-driven solutions for diagnostics, therapeutics, and personalized medicine. Market forces such as rising healthcare demands, regulatory support for innovation, and expanding data capabilities favor Casdin’s investment focus. By funding and guiding companies at the forefront of these trends, Casdin Capital influences the broader ecosystem by accelerating the commercialization of breakthrough technologies and fostering a vibrant startup environment in life sciences[1][3][6].
Looking ahead, Casdin Capital is poised to deepen its impact by continuing to invest in emerging life sciences innovations, including synthetic biology, advanced diagnostics, and healthtech platforms. Trends such as AI-driven drug discovery, gene editing, and precision medicine will likely shape their portfolio and strategy. As the life sciences sector grows more complex and data-intensive, Casdin’s research-driven, collaborative approach positions it to remain a key player in identifying and scaling companies that transform healthcare. Their influence is expected to expand as they leverage their expertise and network to support the next generation of scientific breakthroughs and healthcare solutions[1][3][4].
Key people at Casdin Capital.